Bruker (NASDAQ:BRKR) Lowered to “Hold” Rating by Citigroup

Bruker (NASDAQ:BRKR) was downgraded by investment analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday, Marketbeat reports. They presently have a $40.00 price objective on the medical research company’s stock, down from their previous price objective of $50.00. Citigroup’s price objective points to a potential upside of 10.07% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. UBS Group reduced their price target on shares of Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company dropped their target price on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Stifel Nicolaus reduced their target price on shares of Bruker from $57.00 to $48.00 and set a “hold” rating on the stock in a research report on Thursday, May 8th. Finally, Barclays decreased their price target on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Bruker currently has a consensus rating of “Hold” and an average price target of $59.10.

Bruker Stock Down 0.3%

Shares of NASDAQ:BRKR opened at $36.34 on Thursday. The stock’s 50-day moving average is $39.65 and its 200 day moving average is $49.92. The company has a market cap of $5.51 billion, a PE ratio of 47.82, a P/E/G ratio of 2.16 and a beta of 1.23. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker has a 1 year low of $34.10 and a 1 year high of $78.59.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million for the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $0.53 EPS. Sell-side analysts anticipate that Bruker will post 2.69 EPS for the current year.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently made changes to their positions in BRKR. Pinnacle Bancorp Inc. bought a new position in Bruker in the 1st quarter valued at approximately $29,000. Allworth Financial LP raised its stake in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the last quarter. UMB Bank n.a. increased its holdings in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new stake in Bruker in the 1st quarter worth about $42,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.